Concepedia

Stephen T. Wrobleski

ST

23

Publications

1.6K

Citations

19

H-Index

1996

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Stanford University

Bristol-Myers Squibb (Japan)

University of Rochester

Stephen T. Wrobleski is an author at Bristol-Myers Squibb (United States) specializing in medicine, natural sciences, and drug discovery.

ORCID

Top concepts

Publications per year

1996–2019

23

Publications

23

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 345 citations · Full text

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 268 citations

Ruthenium-Catalyzed Alkene-Alkyne Coupling:  Synthesis of the Proposed Structure of Amphidinolide A

Barry M. Trost, John D. Chisholm, Stephen T. Wrobleski et al. · Journal of the American Chemical Society · 2002 · 91 citations

, , +15

Total Synthesis of (+)-Amphidinolide A. Assembly of the Fragments

Barry M. Trost, Stephen T. Wrobleski, John D. Chisholm et al. · Journal of the American Chemical Society · 2005 · 87 citations

Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)

Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2019 · 84 citations · Full text

Rows per page

1–5 of 23